Gilead Sciences Inc (GILD)
147.45
-0.40%
Gilead Sciences Inc (GILD) is currently trading at $147.45. This represents a loss of 0.4% from the previous session. With a market capitalization of $182.91B, GILD is a key component of the Health Care sector. Investors looking to trade GILD should compare margin rates and options platforms to optimize their portfolio management.
Broker Promotion
Claim Your $300 Cash Bonus →
T&Cs Apply. Trade GILD commission-free.
Trading Platform Comparison
Moomoo
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Good for small traders
IBKR
- Min Deposit: $0
- Commissions: $0–$0.005/share
- Fractional Shares: ✅
- Options: ✅
- Notes: Professional-level tools
Ameritrade
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Strong research tools
Webull
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Easy mobile app
AI Market Sentiment
As of today, Gilead Sciences Inc (GILD) shows a bearish trend. Analysts are watching the 149.11 level closely.
Fundamentals
Mkt Cap182.91B
P/E Ratio0.0000
Volume2,398,822
60-Day Technical Chart
Advanced Charting
Need more indicators for GILD? Use the world's #1 platform.
Open GILD on TradingView →Charting Platforms
TradingView
Advanced charts & indicators, web & mobile
StockCharts
Technical analysis charts with overlays & indicators
BarCharts
Market data, charts, and technical signals
Finviz
Visual stock charts & heatmaps
Yahoo Finance Charts
Basic interactive charts with indicators
Side-by-Side: Stocks Near $147
| Metric |
GILD -0.40% |
PLTR +4.34% |
ORCL +2.51% |
MSTR +8.75% |
|---|---|---|---|---|
| Price | $147.45 | $134.36 | $149.85 | $135.52 |
| Mkt Cap | $182.91B | $321.35B | $429.96B | $43.18B |
| - | View → | View → | View → |
Latest Headlines
Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J
Investor's Business Daily • Feb 23, 2026
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion
Reuters • Feb 23, 2026
Gilead shows belief in its partner’s cancer treatment with $7.8 billion buyout
MarketWatch • Feb 23, 2026
Gilead execs hit TD Cowen, Leerink, Barclays in March webcasts
Stock Titan • Feb 23, 2026
Time To Take Profits On Gilead Sciences (Rating Downgrade) (NASDAQ:GILD)
Seeking Alpha • Feb 20, 2026
● Gemini Agentic AI Analyst Insight for GILD
Market Education
- Want to be a Wall street billionaire, take their investing advice Jul 19, 2023
- Stocks with Cash and Low Debt Dec 10, 2023
- Understanding Hedge Fund Alpha and Beta: A Guide for New Investors Jun 2, 2024
External Research